CN42 Nurse and pharmacist-delivered gynaecology telephone clinic: Maintenance therapies patient and staff survey

Abstract

The analysis with the EORTC QLQeLC13 showed that the CES-D was positively correlated with dyspnoea (r s ¼ .57, p < .01), coughing (r s ¼ .48, p < .01), haemoptysis (r s ¼.49, p < .01) and dysphagia (r s ¼.38, p < .05). However, when these variables were added as predictors of CES-D into a regression model (R 2 ¼ 0,80, p < 0,01) to assess their predictive power, none of them significantly predicted the depression score.Conclusions: Considering the above results, we concluded that depression was associated with quality of life in lung cancer patients with diabetes type 2.Legal entity responsible for the study: The authors.

Developing a nurse-led clinic for patients receiving PARP inhibitors

“…The clinic was led by nurses and pharmacists, with oncology consultant supervision. It was established initially for patients receiving PARP inhibitors and bevacizumab (another drug administered as a maintenance treatment for patients with gynaecological cancers), although patients could be seen in person if required; for example, if they developed mild disease-related symptoms or mild treatment-related toxicity (Jupp et al 2020).…”

“…The remaining 11 patients continued to attend face-to-face clinics. Patients and staff surveys were conducted at the end of the pilot; 19 out of 23 patient surveys and ten out of 13 staff surveys (five doctors, four nurses, one pharmacist) were completed and returned (Jupp et al 2020).…”

“…All ten staff reported that they believed the telephone clinic had supported management of face-to-face clinics while nine reported that they felt very confident in the healthcare professionals who were leading the telephone consultations (Jupp et al 2020).…”

“…Overall, the pilot showed that the telephonebased format was effective, therefore the PARP inhibitor nurse-led clinic was introduced into the trust permanently from February 2020 (Jupp et al 2020).…”

“…The advent of maintenance treatment with PARP inhibitors has radically changed the advanced ovarian cancer follow-up pathway, meaning that more patients require regular follow-up and monitoring (Liu et al 2018). This has in turn increased the demands placed on healthcare services (Jupp et al 2020). As such, there is considerable value in providing specific clinics for patients with ovarian cancer who are receiving maintenance treatment.…”